ASSESSING THE ROLE OF COAGULATION ASSAYS IN THE MANAGEMENT OF BLEEDING DISORDERS: A REVIEW OF LABORATORY TECHNIQUES AND CLINICAL IMPLICATIONS
Main Article Content
Keywords
Coagulation, bleeding disorders, laboratory techniques, clinical implications
Abstract
Coagulation assays are critical tools in the management of bleeding disorders, offering insights into the complex mechanisms of hemostasis and informing clinical decisions. Bleeding disorders present diverse challenges due to their varied pathophysiological bases, necessitating precise diagnostic and management strategies. Traditional assays such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) provide foundational data on the extrinsic and intrinsic pathways of the coagulation cascade but often lack the sensitivity to detect mild deficiencies or to accurately predict bleeding risks in non-hemophilic disorders. Recent advancements have introduced more sophisticated techniques like thromboelastography and chromogenic assays, which deliver a dynamic and comprehensive view of the clotting process. These advanced methods not only improve diagnostic accuracy but also offer timely data crucial for managing acute cases and surgical interventions. However, the adoption of such technologies in everyday clinical practice is hindered by high costs, the need for specialized equipment, and complex interpretation of results. The integration of coagulation tests with detailed clinical evaluations is essential to customize treatment plans effectively, acknowledging the substantial variability in test results due to individual patient factors and external influences. This variability highlights the challenges in interpreting coagulation assays and underscores the necessity of a cautious approach that combines laboratory data with clinical insights. Future developments in coagulation testing are expected to lean towards a hybrid model that leverages both traditional and modern techniques. Ongoing research and clinical validation are crucial to refining these methods, ensuring that coagulation assays continue to evolve as reliable, efficient tools in the management of bleeding disorders, thereby enhancing overall patient care.
References
2. Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia. 2010 Jul;16:85-92.
3. Bonar RA, Lippi G, Favaloro EJ. Overview of hemostasis and thrombosis and contribution of laboratory testing to diagnosis and management of hemostasis and thrombosis disorders. Hemostasis and Thrombosis: Methods and Protocols. 2017:3-27.
4. Favaloro EJ, Bonar R. Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program. InSeminars in thrombosis and hemostasis 2007 Apr (Vol. 33, No. 03, pp. 235-242). Copyright© 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA..
5. Triplett DA. Coagulation and bleeding disorders: review and update. Clinical chemistry. 2000 Aug 1;46(8):1260-9.
6. Ågren A, Wikman AT, Holmström M, Östlund A, Edgren G. Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients–a laboratory evaluation. Scandinavian journal of clinical and laboratory investigation. 2013 Apr 1;73(3):214-20.
7. McHugh J, Holt C, O'Keeffe D. An assessment of the utility of unselected coagulation screening in general hospital practice. Blood coagulation & fibrinolysis. 2011 Mar 1;22(2):106-9.
8. Korpallová B, Samoš M, Bolek T, Škorňová I, Kovář F, Kubisz P, Staško J, Mokáň M. Role of thromboelastography and rotational thromboelastometry in the management of cardiovascular diseases. Clinical and Applied Thrombosis/Hemostasis. 2018 Nov;24(8):1199-207.
9. Garrone P, Grilli L, Groppi A, Marzano R. Barriers and drivers in the adoption of advanced wastewater treatment technologies: a comparative analysis of Italian utilities. Journal of Cleaner Production. 2018 Jan 10;171:S69-78.
10. Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver International. 2013 Aug;33(7):961-74..
11. Shaydakov ME, Sigmon DF, Blebea J. Thromboelastography.
12. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M, British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. International journal of laboratory hematology. 2013 Feb;35(1):1-3.
13. Castellone DD, Adcock DM. Factor VIII activity and inhibitor assays in the diagnosis and treatment of hemophilia A. InSeminars in thrombosis and hemostasis 2017 Apr (Vol. 43, No. 03, pp. 320-330). Thieme Medical Publishers.
14. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis. 2012 Apr;10(4):615-21.
15. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Annals of internal medicine. 2003 Feb 4;138(3):W-15W..